BREAST CANCER DIAGNOSTIC PANEL II (HISTO + ER, PR, HER2, Ki67 IHC)

Test Name

Aliases

BREAST HISTOPATHOLOGY WITH EXTENDED IHC; BREAST HISTOPATHOLOGY AND COMPREHENSIVE IHC PANEL; BREAST HISTOPATHOLOGY WITH PROGNOSTIC/PREDICTIVE IHC PANEL

Abbreviations

BREAST PATH WITH ER/PR/HER2/KI67

Test Classification

GROUPED TEST

Department

ANATOMIC PATHOLOGY

Sub Department

HISTOLOGY

TAT Category

ELAPSED (CONTINUOUS) TIME

Estimated TAT

TAT Units

DAYS

Test Requirements

Provide clinical history, imaging findings, and prior therapy. Acceptable specimens: 1. Fresh breast tissue in 10% neutral buffered formalin (NBF); place in fixative immediately after excision OR 2. FFPE blocks OR 3. Unstained slides (3–5 µm). For IHC positively charged slides. Fixation requirements: 6–72 hours in 10% NBF; avoid over-fixation or under-fixation. Tissue quality: Representative tumor tissue with minimal crush or thermal artifact. Test components: Histology with ER, PR, Ki 67 and HER 2 IHC.

Clinical Utility

Confirms malignancy and subtype. Determines hormone-receptor status to guide endocrine therapy. Determines HER2 status for anti-HER2 therapy eligibility. Forms the basis of molecular surrogate classification (e.g., Luminal vs HER2-enriched vs Basal-like).

Last Review

26th Feb 2026